

## Portfolio Drug Substance

List Products	Therapeutic Areas	Monographs	Regulatory Documentation	DEA Schedule	CAS Number	Produced in
Acemetacin	Nonsteroidal anti-inflammatory	Ph. Eur.	CEP	n.a.	53164-05-9	■
Aminophylline Anhydrous	Bronchodilator	Ph. Eur., USP	CEP	n.a.	317-34-0	◆
Aminophylline Hydrous	Bronchodilator	JP, Ph. Eur., USP	CEP	n.a.	5897-66-5	◆
Amylmetacresol (AMC)	Antiseptic agent	Ph. Eur.	CEP	n.a.	1300-94-3	◆
Articaine HCl	Anesthetic	Ph. Eur., USP	CEP/USDMF	n.a.	23964-57-0	✘
Benoxinate HCl	Anesthetic	Ph. Eur., USP	ASMF/USDMF	n.a.	5987-82-6	■
Benzonate	Antitussive	USP	USDMF	n.a.	104-31-4	■
Bethanechol Chloride	Parasympathomimetic (Cholinergic)	USP	ASMF/USDMF	n.a.	590-63-6	■
Bupivacaine Base	Anesthetic	n.a.	ASMF/USDMF	n.a.	38396-39-3	■
Bupivacaine HCl	Anesthetic	Ph. Eur., USP	CEP/USDMF	n.a.	14252-80-3	■
Butalbital	Sedative	USP	USDMF	III	77-26-9	●
Caffeine Anhydrous	Stimulant	IP, JP, Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	58-08-2	◆
Chloroprocaine HCl	Anesthetic	USP	ASMF/USDMF	n.a.	3858-89-7	■
Choline Salicylate 80%	Analgesic/Anti-inflammatory	n.a.	ASMF/USDMF	n.a.	2016-36-6	■
Cyclizine Base	Antiemetic, Histamine H1 antagonist	n.a.	ASMF	n.a.	82-92-8	✘
Cyclizine HCl	Antiemetic, Histamine H1 antagonist	n.a.	ASMF	n.a.	303-25-3	✘
Dobutamine HCl	Vasopressor	Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	49745-95-1	◆
Dopamine HCl	Vasopressor	JP, Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	62-31-7	◆
Ephedrine HCl	Respiratory system	Ph. Eur., USP	CEP/USDMF	n.a.	50-98-6	◆
Ephedrine Sulphate	Respiratory system	USP	ASMF/USDMF	n.a.	134-72-5	◆
Fluoxetine HCl	Antidepressant	Ph. Eur., USP	CEP	n.a.	59333-67-4	▲
Isotretinoin M	Dermatica	Ph. Eur., USP	CEP/USDMF	n.a.	4759-48-2	◆
Levonordefrine Base	Vasoconstrictor	USP	USDMF	n.a.	829-74-3	■
Levonordefrine HCl	Vasoconstrictor	n.a.	n.a.	n.a.	829-74-3	■
Mepivacaine HCl	Anesthetic	JP, Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	1722-62-9	■
Methenamine Hippurate	Antiseptic agent	USP	USDMF	n.a.	5714-73-8	■
Metolazone	Cardiovascular agent	Ph. Eur., USP	ASMF/USDMF	n.a.	17560-51-9	■

ASMF: Active Substance Mater File

▲  
Siegfried AG  
Switzerland●  
Siegfried USA, LLC  
USA■  
Siegfried Evionnaz SA  
Switzerland◆  
Siegfried  
PharmaChemikalien  
Minden GmbH  
Germany✘  
Siegfried St. Vulbas SAS  
France■  
Siegfried (Nantong)  
Pharmaceuticals Co. Ltd.  
China

For general enquiries, enquiries regarding Siegfried's  
schedule I + schedule II controlled substance and additional information,  
please contact us at [sales@siegfried.ch](mailto:sales@siegfried.ch)

## Portfolio Drug Substance

List Products	Therapeutic Areas	Monographs	Regulatory Documentation	DEA Schedule	CAS Number	Produced in
Naloxone HCl	Opiate antagonist	Ph. Eur., USP	CEP/USDMF	n.a.	51481-60-8	◆
Naltrexone HCl	Opiate antagonist	Ph. Eur., USP	CEP/USDMF	n.a.	16676-29-2	◆
Nifedipine	Antihypertensive	Ph. Eur.	CEP	n.a.	21829-25-4	▲
Oxiconazole Nitrate	Antifungal	n.a.	ASMF/USDMF	n.a.	64211-46-7	▲
Oxymetazoline HCl	Decongestant	JP, Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	2315-02-8	◆
Phenazine Sulphate	Antidepressant, anxiolytic (MAOI)	n.a.	USDMF	n.a.	156-51-4	■
Phenobarbital Sodium	Sedative, anticonvulsant, hypnotic	USP	USDMF	IV	57-30-7	●
Phentermine Base	Anorexic	USP	AUS-DMF	IV	122-09-8	●
Phentermine HCl	Anorexic	USP	USDMF	IV	1197-21-3	●
Phenylephrine HCl	Respiratory system	IP, JP, Ph. Eur., USP	CEP/USDMF	n.a.	61-76-7	◆
Prilocaine Base	Anesthetic	Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	721-50-6	■
Prilocaine HCl	Anesthetic	Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	1786-81-8	■
Primidone	Antiepileptic	Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	125-33-7	▤
Proparacaine HCl	Ophthalmic, anesthetic	BP, USP	ASMF/USDMF	n.a.	5875-06-09	▲
Pseudoephedrine HCl	Respiratory system	JPC, Ph. Eur., USP	CEP/USDMF	n.a.	345-78-8	◆
Pseudoephedrine Sulphate	Respiratory system	USP	ASMF/USDMF	n.a.	7460-12-0	◆
Tetracaine Base	Anesthetic	USP	ASMF/USDMF	n.a.	94-24-6	■
Tetracaine HCl	Anesthetic	JP, Ph. Eur., USP	ASMF/JDMF/USDMF	n.a.	136-47-0	■
Theophylline Anhydrous	Respiratory system	IP, JP, Ph. Eur., USP	CEP/JDMF/USDMF	n.a.	58-55-9	◆
Theophylline Hydrous	Respiratory system	IP, JP, Ph. Eur., USP	CEP/USDMF	n.a.	5967-84-0	◆
Tretinoin M	Dermatica	Ph. Eur., USP	CEP/USDMF	n.a.	302-79-4	◆
Tricaine Methanesulfonate	Anesthetic	n.a.	ASMF	n.a.	886-86-2	■
Xylometazoline HCl	Decongestant	IP, Ph. Eur., USP	CEP/USDMF	n.a.	1218-35-5	◆

ASMF: Active Substance Mater File

Any product descriptions, or services noted on this portfolio list are not intended to constitute offers to sell or solicitations in connection with any products or services. This portfolio list may provide information for products and services that are not available in all jurisdictions.

▲  
Siegfried AG  
Switzerland

●  
Siegfried USA, LLC  
USA

■  
Siegfried Evionnaz SA  
Switzerland

◆  
Siegfried  
PharmaChemikalien  
Minden GmbH  
Germany

×  
Siegfried St. Vulbas SAS  
France

▤  
Siegfried (Nantong)  
Pharmaceuticals Co. Ltd.  
China

For general enquiries, enquiries regarding Siegfried's  
schedule I + schedule II controlled substance and additional information,  
please contact us at [sales@siegfried.ch](mailto:sales@siegfried.ch)

# Development Portfolio Drug Substance

<u>Development Products</u>	<u>Therapeutic Areas</u>	<u>Commercial Availability</u>	<u>Monographs</u>	<u>Regulatory Documentation</u>	<u>DEA Schedule</u>	<u>CAS Number</u>
Naltrexone Base	Opiate antagonist	Standard	n.a.	In development	n.a.	16590-41-3

<sup>1</sup> Clinical Trial Material

Any product descriptions, or services noted on this portfolio list are not intended to constitute offers to sell or solicitations in connection with any products or services. This portfolio list may provide information for products and services that are not available in all jurisdictions.

For general enquiries, enquiries regarding Siegfried's  
schedule I + schedule II controlled substance and additional information,  
please contact us at [sales@siegfried.ch](mailto:sales@siegfried.ch)

## Product List Sterile Application

Dossier	Form	Concentration / Strength	Volume	Territory
Alfentanil inj.	Ampoule & Vial	0.5 mg/ml	1, 2, 10 ml	B
Apomorphine inj.	Ampoule	10 mg/ml	5 ml	A
Atracurium inj.	Ampoule	10 mg/ml	2.5 (3), 5 ml	B
Cisatracurium inj.	Ampoule	2 mg/ml	2, 5, 10 ml	B
Clindamycine inj.	Ampoule	150 mg/ml	2, 4, 6 ml	A
Dexamethasone inj.	Ampoule	4 mg/ml	1, 2, 5, 10 ml	B
Diazepam inj.	Ampoule	5 mg/ml	2 ml	A
Dobutamine inj.	Ampoule/Vial		5, 20, 50 ml	B
Fentanyl inj.	Ampoule	0.05 mg/ml	2, 10 ml	B
Flumazenil inj.	Ampoule	0.1 mg/ml	5, 10 ml	B
Furosemide inj.	Ampoule	10 mg/ml	2, 4, 25 ml	B
Glyceryl Trinitrate inj.	Ampoule, Vial	1 mg/ml	1, 10, 25, 50 ml	B
Granisetron inj.	Vial (single & multidose) Ampoule	0.1, 1 mg/ml 0.1, 1 mg/ml	1, 4 ml 3 ml	A B
Ketamine inj.	Ampoule, Vial	10, 50 mg/ml	2, 5, 10, 20 ml	B
Levofloxacin inj.	Vial	5 mg/ml	50, 100 ml	A
Methotrexate	Prefilled syringe	25 mg/ml	0.3 (0.5), 0.4 (0.5), 0.6 (1), 0.8 (1) ml, 1 (1) ml	C
Metoclopramide inj.	Ampoule	5 mg/ml	2, 10 mg	B
Midazolam inj.	Ampoule	1, 2, 5 mg/ml	1, 2, 3, 5, 10, 18, 25 ml	B
Morphine Sulfate inf.	Vial, Ampoule	1, 2, 10, 15, 20 mg/ml	1, 5, 10, 50, 100 ml	B
Naloxone inj.	Ampoule	0.02, 0.4 mg/ml	1, 2 ml	B
Neostigmine	Ampoule	0.5, 2.5 mg/ml	1 ml	A
Ondansetron inj.	Vial (single & multidose) Ampoule	2 mg/ml 2 mg/ml	2 ml, 20 ml 2 ml, 4 (5) ml	A B
Levofloxacin inj.	Vial	5 mg/ml	100 ml	A
Palonosetron	Vial	5 µg/ml	5 ml	A
Pethidine inj.	Ampoule	50 mg/ml	1, 2 ml	A
Remifentanyl inj.	Vial (lyo)	1, 2, 5 mg		B
Rocuronium inj.	Vial	10 mg/ml	2.5 (2), 5 (6), 10 ml	B
Sufentanil inj.	Ampoule	0.005, 0.05 mg/ml	1, 2, 5, 10, 15, 20 ml	B
Thioctacid inj.	Ampoule/Bottle	25 mg/ml / 6, 12 mg/ml	12, 24, 50, 100 ml	A
Tramadol inj.	Ampoule	50 mg/ml	1, 2 ml	B
Zoledronic acid	Plastic vial	4 mg/5 ml	5 ml	B

Territory A: Worldwide

Territory B: Worldwide excluding the below mentioned countries: Austria, Denmark, Germany, Finland, France, Great Britain, Greece, Ireland, Spain, Italy, The Netherlands, Norway, Portugal, Sweden, Switzerland, Turkey, Brazil, Mexico, Chile, Panama, Venezuela, Colombia, Canada, Israel, Jordan, Kuwait, Lebanon, Saudi Arabia, UAE, Yemen, Bahrain, Oman, Hong Kong, Indonesia, Malaysia, Pakistan, Singapore, Sri Lanka, Vietnam, New Zealand, Australia, Thailand, Taiwan, Philippines, Libya, Kenya, Egypt, Republic of South Africa (South Africa with respect to the Dossiers relating to Remifentanyl, Alfentanil, Rocuronium and Cisatracurium only)

Territory C: Europe

Siegfried Hameln, Germany

For enquiries and additional information,  
please contact us at [sales@siegfried.ch](mailto:sales@siegfried.ch)

## Product List Oral Formulation

<b>INN</b>	<b>Therapeutic Areas</b>	<b>Formulation / Dosage</b>	<b>CTD-Format Availability</b>
Amlodipine Besylate	Hypertension	Tablet 5, 10 mg	Available
Amlodipine Mesylate	Hypertension	Tablet 5, 10 mg	Available
Candesartan Candesartan/HCT	Hypertension	Tablet 4, 8, 16, 32 mg 8 / 12.5, 16 / 12.5 mg	Available
Doxazosin	Hypertension	Tablet 1, 2, 4 mg	Available
Felodipine	Hypertension	SR Tablet 2.5, 5, 10 mg	Available
Finasteride	Benign Prostate Hyperplasia	Tablet 5 mg	Available
Fluoxetine	Depression	Capsule 20 mg Tablet 10 mg Tablet 20 mg	Available On request Available
Imatinib	Chronic Myeloid Leukaemia	Film-coated tablet 100, 400 mg	Available
Latanoprost	Glaucoma / Ocular Hypertension	Solution 2.5 ml (0.005%)	Available
Nifedipine	Hypertension	SR Tablet 40 mg	Available
Sitagliptin	Diabetes	Film-coated tablet 25, 50, 100 mg	Available
Tamsulosine	Benign Prostate Hyperplasia	Capsule 0.4 mg	Available

Any product descriptions, or services noted on this portfolio list are not intended to constitute offers to sell or solicitations in connection with any products or services. This portfolio list may provide information for products and services that are not available in all jurisdictions.

Siegfried Malta Ltd, Malta

For enquiries and additional information,  
please contact us at [sales@siegfried.ch](mailto:sales@siegfried.ch)